{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:10:47Z","timestamp":1758280247776},"reference-count":50,"publisher":"Japan Atherosclerosis Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.5551\/jat.47167","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T17:29:19Z","timestamp":1548178159000},"page":"738-745","source":"Crossref","is-referenced-by-count":13,"title":["Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study"],"prefix":"10.5551","volume":"26","author":[{"given":"Ran","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Preventive Medicine, Chonnam National University Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye-Ran","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Nursing, Nambu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Ho","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Chonnam National University Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Nam","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Chonnam National University Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine & Institute of Wonkwang Medical Science, Wonkwang University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong-Woo","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Chosun University Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Seog","family":"Kweon","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Chonnam National University Medical School"},{"name":"Jeonnam Regional Cancer Center, Chonnam National University Hwasun Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Mortality GBD and Causes of Death C: Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015; 385: 117-171","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"2","unstructured":"2) In: Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health, ed by Fuster V and Kelly BB, Washington (DC), 2010"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Frostegard J: Immunity, atherosclerosis and cardiovascular disease. BMC Med, 2013; 11: 117","DOI":"10.1186\/1741-7015-11-117"},{"key":"4","unstructured":"4) Montagnana M, Lippi G, Salvagno GL, Franchini M, Targher G and Guidi GC: [Role of biochemical risk factors and markers for the risk of atherosclerosis]. Recenti progressi in medicina, 2008; 99: 215-222"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Jr., Taubert K, Tracy RP, Vinicor F, Centers for Disease C, Prevention and American Heart A: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 2003; 107: 499-511","DOI":"10.1161\/01.CIR.0000052939.59093.45"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Vilahur G and Badimon L: Biological actions of pentraxins. Vascul Pharmacol, 2015; 73: 38-44","DOI":"10.1016\/j.vph.2015.05.001"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Miyamoto T, Rashid Qureshi A, Heimburger O, Barany P, Carrero K, Sjoberg B, Lindholm B, Stenvinkel P and Carrero JJ: Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clin J Am Soc Nephrol, 2011; 6: 2785-2791","DOI":"10.2215\/CJN.02320311"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I, Kurata T, Ota H, Mantovani A, Hamakubo T, Daida H and Kodama T: Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol, 2007; 27: 161-167","DOI":"10.1161\/01.ATV.0000252126.48375.d5"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, Pizzetti F, Maggioni AP, Moccetti T, Metra M, Cas LD, Ghezzi P, Sipe JD, Re G, Olivetti G, Mantovani A and Latini R: PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation, 2000; 102: 636-641","DOI":"10.1161\/01.CIR.102.6.636"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Tazaki R, Tanigawa J, Fujisaka T, Shibata K, Takeda Y, Ishihara T, Hoshiga M, Hanafusa T and Ishizaka N: Plasma Pentraxin3 Level Is Associated With Plaque Vulnerability Assessed by Optical Coherence Tomography in Patients With Coronary Artery Disease. Int Heart J, 2016; 57: 18-24","DOI":"10.1536\/ihj.15-248"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Jenny NS, Blumenthal RS, Kronmal RA, Rotter JI, Siscovick DS and Psaty BM: Associations of pentraxin 3 with cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost, 2014; 12: 999-1005","DOI":"10.1111\/jth.12557"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Altay S, Cakmak HA, Kemaloglu Oz T, Ozpamuk Karadeniz F, Turer A, Erer HB, Kilic GF, Keles I, Can G and Eren M: Long-term prognostic significance of pentraxin-3 in patients with acute myocardial infarction: 5-year prospective cohort study. Anatol J Cardiol, 2017; 17: 202- 209","DOI":"10.14744\/AnatolJCardiol.2016.7307"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, Vago L, Pasqualini F, Signorini S, Soldateschi D, Tarli L, Schweiger C, Fresco C, Cecere R, Tognoni G, Mantovani A and Lipid Assessment Trial Italian Network I: Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation, 2004; 110: 2349-2354","DOI":"10.1161\/01.CIR.0000145167.30987.2E"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Dubin R, Li Y, Ix JH, Shlipak MG, Whooley M and Peralta CA: Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J, 2012; 163: 274-279","DOI":"10.1016\/j.ahj.2011.11.007"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Norata GD, Garlanda C and Catapano AL: The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends in cardiovascular medicine, 2010; 20: 35-40","DOI":"10.1016\/j.tcm.2010.03.005"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Shiraki A, Kotooka N, Komoda H, Hirase T, Oyama JI and Node K: Pentraxin-3 regulates the inflammatory activity of macrophages. Biochem Biophys Rep, 2016; 5: 290-295","DOI":"10.1016\/j.bbrep.2016.01.009"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G and Mantovani A: Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis, 2004; 175: 221-228","DOI":"10.1016\/j.atherosclerosis.2004.03.020"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Zanetti M, Bosutti A, Ferreira C, Vinci P, Biolo G, Fonda M, Valente M, Cattin L, Guarnieri G and Barazzoni R: Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clinical and experimental medicine, 2009; 9: 243-248","DOI":"10.1007\/s10238-009-0039-z"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Zanetti M, Zenti M, Barazzoni R, Zardi F, Semolic A, Messa MG, Mearelli F, Russi G, Fonda M, Scarano L, Bonora E and Cattin L: HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia. PloS one, 2014; 9: e101290","DOI":"10.1371\/journal.pone.0101290"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, Garlanda C, Mantovani A and Catapano AL: Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol, 2008; 28: 925-931","DOI":"10.1161\/ATVBAHA.107.160606"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kweon SS, Shin MH, Jeong SK, Nam HS, Lee YH, Park KS, Ryu SY, Choi SW, Kim BH, Rhee JA, Zheng W and Choi JS: Cohort Profile: The Namwon Study and the Dong-gu Study. Int J Epidemiol, 2014; 43: 558-567","DOI":"10.1093\/ije\/dys244"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Lee YH, Shin MH, Choi JS, Rhee JA, Nam HS, Jeong SK, Park KS, Ryu SY, Choi SW, Kim BH, Oh GJ and Kweon SS: HbA1c is significantly associated with arterial stiffness but not with carotid atherosclerosis in a community-based population without type 2 diabetes: The Dong-gu study. Atherosclerosis, 2016; 247: 1-6","DOI":"10.1016\/j.atherosclerosis.2016.01.032"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Lee R, Ahn HR, Shin MH, Kim HN, Lee YH, Choi SW and Kweon SS: Association between Plasma Pentraxin 3 Levels and Bone Mineral Density in Elderly Koreans: the Dong-gu Study. J Korean Med Sci, 2018; 33: e165","DOI":"10.3346\/jkms.2018.33.e165"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Fatar M, Hernandez Hernandez R, Jaff M, Kownator S, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS, Zannad F and Zureik M: Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis, 2007; 23: 75-80","DOI":"10.1159\/000097034"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kweon SS, Lee YH, Shin MH, Choi JS, Rhee JA, Choi SW, Ryu SY, Kim BH, Nam HS, Jeong SK and Park KS: Effects of cumulative smoking exposure and duration of smoking cessation on carotid artery structure. Circ J, 2012; 76: 2041-2047","DOI":"10.1253\/circj.CJ-11-1353"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I and et al.: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr, 1989; 2: 358-367","DOI":"10.1016\/S0894-7317(89)80014-8"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C, National Heart L, Blood I and American Heart A: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol, 2004; 24: e13-18","DOI":"10.1161\/01.ATV.0000111245.75752.C6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G and National Kidney F: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med, 2003; 139: 137-147","DOI":"10.7326\/0003-4819-139-2-200307150-00013"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Magrini E, Mantovani A and Garlanda C: The Dual Complexity of PTX3 in Health and Disease: A Balancing Act? Trends Mol Med, 2016; 22: 497-510","DOI":"10.1016\/j.molmed.2016.04.007"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Sun H, Tian J, Xian W, Xie T and Yang X: Pentraxin-3 Attenuates Renal Damage in Diabetic Nephropathy by Promoting M2 Macrophage Differentiation. Inflammation, 2015; 38: 1739-1747","DOI":"10.1007\/s10753-015-0151-z"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Miyaki A, Maeda S, Yoshizawa M, Misono M, Sasai H, Shimojo N, Tanaka K and Ajisaka R: Is pentraxin 3 involved in obesity-induced decrease in arterial distensibility? J Atheroscler Thromb, 2010; 17: 278-284","DOI":"10.5551\/jat.2741"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Alberti L, Gilardini L, Zulian A, Micheletto G, Peri G, Doni A, Mantovani A and Invitti C: Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis, 2009; 202: 455-460","DOI":"10.1016\/j.atherosclerosis.2008.05.015"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Kasai T, Inoue K, Kumagai T, Kato M, Kawana F, Sagara M, Ishiwata S, Ohno M, Yamaguchi T, Momomura S and Narui K: Plasma pentraxin3 and arterial stiffness in men with obstructive sleep apnea. Am J Hypertens, 2011; 24: 401-407","DOI":"10.1038\/ajh.2010.248"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Dubin R, Shlipak M, Li Y, Ix J, de Boer IH, Jenny N and Peralta CA: Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis. Nephrol Dial Transplant, 2011; 26: 1903-1908","DOI":"10.1093\/ndt\/gfq648"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kardas F, Akin L, Kurtoglu S, Kendirci M and Kardas Z: Plasma Pentraxin 3 as a biomarker of metabolic syndrome. Indian J Pediatr, 2015; 82: 35-38","DOI":"10.1007\/s12098-014-1542-0"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Vukovic-Dejanovic V, Bogavac-Stanojevic N, Spasic S, Spasojevic-Kalimanovska V, Kalimanovska-Ostric D, Topalovic M and Jelic-Ivanovic Z: Association of Serum Pentraxin-3 and High-Sensitivity C-Reactive Protein with the Extent of Coronary Stenosis in Patients Undergoing Coronary Angiography. J Med Biochem, 2015; 34: 440-449","DOI":"10.2478\/jomb-2014-0061"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Inoue K, Kodama T and Daida H: Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med, 2012; 2012: 657025","DOI":"10.1155\/2012\/657025"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A and Catapano AL: Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis.Circulation, 2009; 120: 699-708","DOI":"10.1161\/CIRCULATIONAHA.108.806547"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Inoue K: The cardioprotective role of pentraxin 3. J Atheroscler Thromb, 2015; 22: 335-337","DOI":"10.5551\/jat.ED011"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Ishino M, Shishido T, Suzuki S, Katoh S, Sasaki T, Funayama A, Netsu S, Hasegawa H, Honda S, Takahashi H, Arimoto T, Miyashita T, Miyamoto T, Watanabe T, Takeishi Y and Kubota I: Deficiency of Long Pentraxin PTX3 Promoted Neointimal Hyperplasia after Vascular Injury. J Atheroscler Thromb, 2015; 22: 372-378","DOI":"10.5551\/jat.26740"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Salio M, Chimenti S, De Angelis N, Molla F, Maina V, Nebuloni M, Pasqualini F, Latini R, Garlanda C and Mantovani A: Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation, 2008; 117: 1055-1064","DOI":"10.1161\/CIRCULATIONAHA.107.749234"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Witasp A, Carrero JJ, Michaelsson K, Ahlstrom H, Kullberg J, Adamsson V, Riserus U, Larsson A, Helmersson- Karlqvist J, Lind L, Stenvinkel P and Arnlov J: Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss. Obesity (Silver Spring), 2014; 22: 1373-1379","DOI":"10.1002\/oby.20695"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T and Inoue K: Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clinical chemistry and laboratory medicine, 2009; 47: 471-477","DOI":"10.1515\/CCLM.2009.110"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Ogawa T, Kawano Y, Imamura T, Kawakita K, Sagara M, Matsuo T, Kakitsubata Y, Ishikawa T, Kitamura K, Hatakeyama K, Asada Y and Kodama T: Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity (Silver Spring), 2010; 18: 1871-1874","DOI":"10.1038\/oby.2009.507"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Osorio-Conles O, Guitart M, Chacon MR, Maymo-Masip E, Moreno-Navarrete JM, Montori-Grau M, Naf S, Fernandez-Real JM, Vendrell J and Gomez-Foix AM: Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity. Am J Physiol Endocrinol Metab, 2011; 301: E1254-1261","DOI":"10.1152\/ajpendo.00163.2011"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Bosutti A, Malaponte G, Zanetti M, Castellino P, Heer M, Guarnieri G and Biolo G: Calorie restriction modulates inactivity-induced changes in the inflammatory markers C-reactive protein and pentraxin-3. J Clin Endocrinol Metab, 2008; 93: 3226-3229","DOI":"10.1210\/jc.2007-1684"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Tomandlova M, Jarkovsky J, Tomandl J, Kubkova L, Kala P, Littnerova S, Gottwaldova J, Kubena P, Ganovska E, Poloczek M, Spinar J, Mueller C, Mebazaa A, Pavkova Goldbergova M and Parenica J: Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress. Dis Markers, 2015; 2015: 159051","DOI":"10.1155\/2015\/159051"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble WJ, Gingras AR, Tzima S, Vivanco F, Egido J, Tijsma O, Hack EC, Daha MR and Roos A: Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol, 2003; 33: 465-473","DOI":"10.1002\/immu.200310022"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Norata GD, Callegari E, Marchesi M, Chiesa G, Eriksson P and Catapano AL: High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation, 2005; 111: 2805-2811","DOI":"10.1161\/CIRCULATIONAHA.104.472886"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Soeki T, Niki T, Kusunose K, Bando S, Hirata Y, Tomita N, Yamaguchi K, Koshiba K, Yagi S, Taketani Y, Iwase T, Yamada H, Wakatsuki T, Akaike M and Sata M: Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. J Cardiol, 2011; 58: 151-157","DOI":"10.1016\/j.jjcc.2011.04.005"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/8\/26_47167\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T23:46:31Z","timestamp":1564789591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/8\/26_47167\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.47167","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}